New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
16:03 EDTLGNDLigand Pharmaceuticals sees 2013 EPS 35c-39c, consensus 39c
Sees 2013 revenue $41M-$44M, consensus $43.2M.
News For LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
09:01 EDTLGNDLigand enters license, supply agreement with Sanofi
Subscribe for More Information
July 24, 2015
12:44 EDTLGNDAmgen announces FDA approval of expanded Kyprolis indication
Subscribe for More Information
12:27 EDTLGNDFDA approves expanded use of Kyprolis in multiple myeloma patients
The FDA announced that on July 24 the administration approved carfilzomib, or Kyprolis, marketed by Onyx Pharmaceuticals, an Amgen (AMGN) subsidiary, in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. The revised labeling includes new Warnings and Precautions for VTE, cardiac toxicities, acute renal failure, pulmonary toxicities, and hypertension. The increased safety risks, including mortality, for elderly patients is described. Detailed safety information in the prescribing information was also updated for use of carfilzomib monotherapy. Reference Link
09:02 EDTLGNDLigand says Revolade recommended by CHMP for EU approval for SAA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use